These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 6199784)

  • 1. [Deficiencies of interferon production in children].
    Virelizier JL
    Presse Med; 1984 Feb; 13(8):495-8. PubMed ID: 6199784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are there pathological defects of interferon secretion in man?
    Virelizier JL
    Biomedicine; 1980 Oct; 32(3):105-7. PubMed ID: 6160881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer and killer cell activities in patients with primary immunodeficiencies or defects in immune interferon production.
    Lipinski M; Virelizier JL; Tursz T; Griscelli C
    Eur J Immunol; 1980 Apr; 10(4):246-9. PubMed ID: 6156843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deficient natural killer cell activity in a patient with Fanconi's anaemia and squamous cell carcinoma. Association with defect in interferon release.
    Hersey P; Edwards A; Lewis R; Kemp A; McInnes J
    Clin Exp Immunol; 1982 Apr; 48(1):205-12. PubMed ID: 6177461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defense mechanisms against primary influenza virus infection in mice. I. The roles of interferon and neutralizing antibodies and thymus dependence of interferon and antibody production.
    Iwasaki T; Nozima T
    J Immunol; 1977 Jan; 118(1):256-63. PubMed ID: 401512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medullasin enhances human natural killer cell activity by a mechanism other than the induction of interferons or interleukin-2.
    Aoki Y; Fukuchi K
    Jpn J Cancer Res; 1987 Jan; 78(1):68-73. PubMed ID: 2434455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Release of lymphokines after Epstein Barr virus infection in vitro. I. Sources of and kinetics of production of interferons and interleukins in normal humans.
    Lotz M; Tsoukas CD; Fong S; Dinarello CA; Carson DA; Vaughan JH
    J Immunol; 1986 May; 136(10):3636-42. PubMed ID: 3009608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects.
    Ortaldo JR; Mason AT; Gerard JP; Henderson LE; Farrar W; Hopkins RF; Herberman RB; Rabin H
    J Immunol; 1984 Aug; 133(2):779-83. PubMed ID: 6203980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon activation and innate immunity.
    Le Page C; Génin P; Baines MG; Hiscott J
    Rev Immunogenet; 2000; 2(3):374-86. PubMed ID: 11256746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of immune interferon is regulated by more than T cell subset: Lyt-1,2,3 and Qat-5 phenotypes of murine T lymphocytes involved in IFN-gamma production in primary and secondary mixed lymphocyte reaction.
    Landolfo S; Kirchner H; Simon MM
    Eur J Immunol; 1982 Apr; 12(4):295-9. PubMed ID: 6178601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of T-cell response in autologous mixed lymphocyte-tumor culture by large granular lymphocytes.
    Uchida A; Klein E
    J Natl Cancer Inst; 1986 Mar; 76(3):389-98. PubMed ID: 2419621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interferon deficiency syndrome in children with lymphosarcoma].
    Mentkevich GL; Zhdanov LV; Makhonova LA; Orlova TG
    Vopr Virusol; 1987; 32(3):334-7. PubMed ID: 2445110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-mediated immunity in nutritional deficiency.
    McMurray DN
    Prog Food Nutr Sci; 1984; 8(3-4):193-228. PubMed ID: 6396715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological functions of macrophages and their regulation by interferons.
    Virelizier JL; Arenzana-Seisdedos F
    Med Biol; 1985; 63(4):149-59. PubMed ID: 2419711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple immuno-regulatory defects in type-1 diabetes.
    Kukreja A; Cost G; Marker J; Zhang C; Sun Z; Lin-Su K; Ten S; Sanz M; Exley M; Wilson B; Porcelli S; Maclaren N
    J Clin Invest; 2002 Jan; 109(1):131-40. PubMed ID: 11781358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lymphokine production in vitro by blood lymphocytes from patients with a defective or hyperactive immune system].
    Gronewold P; Northoff H; Kirchner H; Peter HH
    Immun Infekt; 1984 Nov; 12(6):287-97. PubMed ID: 6210244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T lymphocyte signalling defects and immunodeficiency due to the lack of CD3 gamma.
    Arnaiz-Villena A; Timon M; Rodriguez-Gallego C; Iglesias-Casarrubios P; Pacheco A; Regueiro JR
    Immunodeficiency; 1993; 4(1-4):121-9. PubMed ID: 7909475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic effects of interleukin 2 in primary immunodeficiency diseases.
    Flomenberg N; Welte K; Mertelsmann R; Kernan N; Ciobanu N; Venuta S; Feldman S; Kruger G; Kirkpatrick D; Dupont B; O'Reilly R
    J Immunol; 1983 Jun; 130(6):2644-50. PubMed ID: 6222111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer cells and interferon.
    Welsh RM
    Crit Rev Immunol; 1984; 5(1):55-93. PubMed ID: 6085941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
    Yoo EK; Cassin M; Lessin SR; Rook AH
    J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.